Eggerthella lenta is a gram-positive bacterium that belongs to the Firmicutes phylum, specifically within the Coriobacteriaceae family. This anaerobic organism was first described in the 1980s and has since garnered attention for its significant role in human gut microbiota. Eggerthella lenta is particularly recognized for its ability to metabolize a variety of dietary components and medications, contributing to its function as a potential biomarker in various health contexts. Research has indicated its involvement in the metabolism of certain pharmaceuticals, including the conversion of specific drugs into active or inactive forms, thereby influencing therapeutic outcomes. Recent studies have also tied the presence and abundance of Eggerthella lenta to conditions such as cardiovascular health and metabolic disorders, making it an essential focus for researchers exploring the intricate relationships between gut microbiota and human health.

Elevated levels of Eggerthella lenta may indicate a higher propensity for butyrate production, which can positively influence gut health and metabolic processes. This can be associated with beneficial dietary patterns or effective fiber intake. Conversely, low levels of Eggerthella lenta may suggest a reduced capacity for butyrate synthesis, potentially indicating altered gut microbiota composition or dysbiosis. This could contribute to gastrointestinal discomfort, increased inflammation, or a higher risk of metabolic imbalances. Monitoring the levels of this biomarker can provide insights into overall gut health and help guide dietary or therapeutic interventions.

Eggerthella lenta is a vital biomarker featured in the Gut Zoomer panel, which assesses a comprehensive range of gut microbes, metabolic activity, and intestinal health indicators. Its presence or abundance can provide insights into the gut microbiome's role in metabolic processes and overall health. By analyzing Eggerthella lenta, practitioners can gain deeper understanding of potential metabolic dysregulations and their implications for personalized health strategies.